Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Almost 300 million people globally have chronic hepatitis B
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Evinova will operate as a separate health-tech business within AstraZeneca
Decision on EU marketing authorisation expected for momelotinib by early 2024
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated